Literature DB >> 6403211

Serotypes of Neisseria meningitidis associated with an increased incidence of meningitis cases in the Hamilton area, Ontario, during 1978 and 1979.

F E Ashton, J A Ryan, C Jones, B R Brodeur, B B Diena.   

Abstract

The distribution of serotypes among strains of Neisseria meningitidis responsible for a marked increase of meningitis cases in the Hamilton area, Ontario, in 1978 and 1979 was determined. Twenty-six serogroup B and two serogroup W135 strains isolated from cerebrospinal fluid, blood, and skin of 28 patients were serotyped by agar gel double diffusion. Twenty-one (81%) of the group B strains were serotype 2b as judged by the formation of characteristic serotype precipitin bands with the specific anti-2996 (type 2b) serum. Fourteen of the serotype 2b strains also reacted with anti-77252 serum, which suggested that one strain or several closely related strains were mainly responsible for the increase in meningitis during the 2-year period. Examination of the outer membrane complexes (OMC) of the strains by polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate (SDS-PAGE) revealed that all 21 of the serotype 2b strains contained the class 2 protein (molecular weight 41500) which is known to be the site of the serotype 2b determinant. Further characterization of the serotype 2b, 77252 strains by enzyme-linked immunosorbent assays (ELISA) and SDS-PAGE suggested that the 77252 determinant was present in the class 1 proteins of these strains. The serotype 2b containing strains were isolated from 77.7 and 70% of males and females, respectively, from 81.8% of children less than 5 years of age, and from 75.0% of patients of all age groups. The study indicates the important role of serotype 2b meningococci in causing the increased incidence of meningitis and further substantiates the important association of the serotype 2b determinant with group B serotype 2 meningococcal disease in Canada.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6403211     DOI: 10.1139/m83-020

Source DB:  PubMed          Journal:  Can J Microbiol        ISSN: 0008-4166            Impact factor:   2.419


  7 in total

1.  Human immune response to meningococcal outer membrane protein epitopes after natural infection or vaccination.

Authors:  R E Mandrell; W D Zollinger
Journal:  Infect Immun       Date:  1989-05       Impact factor: 3.441

2.  Monoclonal antibodies to serotype 2 and serotype 15 outer membrane proteins of Neisseria meningitidis and their use in serotyping.

Authors:  W D Zollinger; E E Moran; H Connelly; R E Mandrell; B Brandt
Journal:  Infect Immun       Date:  1984-10       Impact factor: 3.441

3.  Ongoing group B Neisseria meningitidis epidemic in São Paulo, Brazil, due to increased prevalence of a single clone of the ET-5 complex.

Authors:  C T Sacchi; L L Pessoa; S R Ramos; L G Milagres; M C Camargo; N T Hidalgo; C E Melles; D A Caugant; C E Frasch
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

4.  Carriage of Neisseria species in communities with different rates of meningococcal disease.

Authors:  N Le Saux; F Ashton; M Rahman; A Ryan; E Ellis; S Tamblyn; J Morris; A Borczyk; C Mallory; D Mikel; S Thompson; L Black; B Lacey; C Anand
Journal:  Can J Infect Dis       Date:  1992-03

5.  Genetic relationships and clonal population structure of serotype 2 strains of Neisseria meningitidis.

Authors:  D A Caugant; W D Zollinger; L F Mocca; C E Frasch; T S Whittam; L O Frøholm; R K Selander
Journal:  Infect Immun       Date:  1987-06       Impact factor: 3.441

6.  Development of a Neisseria meningitidis group B serotype 2b protein vaccine and evaluation in a mouse model.

Authors:  L Y Wang; C E Frasch
Journal:  Infect Immun       Date:  1984-11       Impact factor: 3.441

7.  Protection against infection with Neisseria meningitidis group B serotype 2b by passive immunization with serotype-specific monoclonal antibody.

Authors:  B R Brodeur; Y Larose; P Tsang; J Hamel; F Ashton; A Ryan
Journal:  Infect Immun       Date:  1985-11       Impact factor: 3.441

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.